By: ABRS- Academic Team
Introduction
A map covered with country markers can create a powerful first impression. It suggests scale, reach, and immediate access to clinical research professionals around the world. Yet for sponsors preparing to initiate or expand a global clinical program, geographic presence alone provides limited assurance.
Knowing someone in a country is not the same as having a qualified professional who is available, appropriately experienced, contractually ready, supported by an operational structure, and capable of working within the sponsor’s systems and expectations. The difference becomes visible when a study moves from planning to execution and theoretical coverage must become reliable delivery.
True global capability is demonstrated through action. Can the provider identify the right professional for a specific function and therapeutic area? Does that person understand the country’s regulatory and healthcare environment? Can the provider complete onboarding efficiently? Is there a governance structure supporting performance, communication, escalation, and continuity?
These questions matter because global clinical operations are not simply the same activities repeated in different locations. Each market brings its own regulatory pathways, site practices, languages, cultural expectations, infrastructure, and workforce conditions. Sponsors therefore need an FSP partner that can provide consistent standards without treating every country as operationally identical.
A credible global FSP model connects three elements: regional knowledge, qualified professionals, and an operating system that allows those professionals to deliver consistently. Without all three, international coverage may exist on paper but remain difficult to activate when a study needs it.
A Map Does Not Prove Operational Readiness
International clinical development requires more than identifying the countries in which a provider claims to operate. Before a market can become part of a functional delivery strategy, the provider must understand what executing the study in that location will involve.
Regulatory pathways, ethics-review processes, contracting practices, documentation expectations, importation requirements, healthcare infrastructure, language, site relationships, and standard medical practices can differ substantially between countries. These differences influence how quickly a study can start, which sites are appropriate, how professionals interact with investigators, and how operational risks must be managed.
The ICH E17 guideline for multi-regional clinical trials recognizes that regional differences may affect both study execution and the interpretation of results. It encourages early consideration of intrinsic and extrinsic regional factors and emphasizes the importance of consistent quality, investigator training, and monitoring across every participating region (International Council for Harmonisation, 2017).
Although ICH E17 primarily addresses the planning and design of multi-regional clinical trials, its underlying message also has operational significance: global consistency cannot be achieved by ignoring regional variation. It depends on understanding that variation early enough to incorporate it into study planning and execution.
Even when regulatory processes are harmonized, local responsibilities do not disappear. The European Union’s Clinical Trials Regulation provides a single submission pathway through the Clinical Trials Information System, but the evaluation, authorization, and supervision of clinical trials remain responsibilities of EU and EEA countries (European Medicines Agency, 2026).
A provider may therefore understand how to navigate CTIS centrally while still lacking the country-level knowledge needed to support interactions with sites, ethics bodies, competent authorities, or local study teams. Harmonization can improve coordination, but it does not eliminate the operational realities within each jurisdiction.
Sponsors evaluating an FSP partner should look beyond the geographic footprint presented in marketing materials. They should determine whether the provider can explain how delivery will work in the relevant countries, including the professionals available, the expected onboarding process, anticipated regulatory or operational challenges, and the support structure behind the regional team.
At ABRS, global coverage is developed through relationships with experienced clinical research professionals who understand the environments in which they work. Our model connects regional expertise with a broader global operating structure, allowing sponsors to obtain country-specific support while maintaining alignment with study-wide expectations.
The objective is not to claim that every country functions in the same way. It is to provide sponsors with a model capable of recognizing local differences and translating them into informed operational decisions.
Capability Lives in People, Not Databases
A large candidate database can be useful, but it should not be confused with an operationally ready workforce. A name, résumé, or previous conversation does not automatically represent current delivery capacity.
Clinical research professionals may change employers, accept new projects, relocate, adjust their availability, or develop new therapeutic and functional experience. Their ability to participate may also depend on contractual restrictions, local employment requirements, travel expectations, language, working hours, and the specific systems used by the sponsor.
For these reasons, global capacity must be continuously evaluated. An FSP provider should know not only who is in its network, but also who is appropriate and realistically available for the work being discussed.
ICH E6(R3) establishes that sponsors should have sufficient resources to conduct a trial and should use appropriately qualified individuals for their assigned activities. It also places responsibility on the sponsor to evaluate whether a service provider is suitable and capable of performing the activities being transferred (International Council for Harmonisation, 2025).
This expectation makes provider selection more substantive than confirming that the organization has access to a certain role in a certain country. Sponsors need confidence that the proposed professionals have the experience, competence, availability, and support required for the specific assignment.
Professional capability is also broader than familiarity with Good Clinical Practice. The Association of Clinical Research Professionals’ competency framework includes multiple domains, such as scientific concepts, participant safety, regulatory knowledge, study operations, site management, data management, leadership, communication, and teamwork. This illustrates why years of experience alone do not fully establish readiness for a particular role (Association of Clinical Research Professionals, 2026).
For example, two Clinical Research Associates may have worked for the same number of years but bring very different capabilities. One may have extensive oncology experience, strong site relationships, and familiarity with complex endpoints, while another may be better suited to vaccine, device, or decentralized studies. The correct selection depends on the protocol, sites, risk profile, systems, travel requirements, and sponsor expectations.
Sponsors should therefore expect an FSP provider to perform a role-specific assessment rather than simply forward available résumés. That assessment should consider education, clinical research experience, therapeutic background, country knowledge, language, technology, communication skills, availability, and the ability to work effectively within the proposed delivery model.
The provider should also distinguish between potential access and confirmed capacity. A professional who might be interested in a future opportunity represents potential coverage. A professional who has been evaluated, has confirmed availability, understands the assignment, and can complete onboarding within the required timeline represents a more credible level of capacity.
The ABRS Global FSP model is supported by an international network of clinical research professionals across multiple functions and regions. However, the value of this network is not based solely on its size. Professionals are considered in relation to the requirements of each opportunity so that therapeutic experience, functional competence, location, language, availability, and sponsor needs can be evaluated together.
This approach enables ABRS to present sponsors with professionals selected for the actual assignment rather than relying exclusively on general profiles. It also allows us to identify honestly when capacity is immediately available, when additional preparation is needed, or when a more specialized search should be conducted.
Scalable Delivery Requires a System Behind the Professional
Even highly experienced professionals can struggle when the operating environment around them is unclear. Global delivery depends not only on individual expertise but also on the processes that connect each professional to the sponsor, the study, and the rest of the clinical team.
A professional needs to know what is expected, which procedures apply, where information is maintained, how performance will be evaluated, and when an issue must be escalated. Without that structure, a sponsor may receive inconsistent execution across countries even when every individual has strong qualifications.
ICH E6(R3) reflects this broader view of provider capability. In addition to requiring sponsors to assess provider suitability, it states that sponsors should have access to relevant information such as procedures and performance metrics. It also expects important transferred activities to receive appropriate oversight and requires service providers to apply suitable quality-management processes (International Council for Harmonisation, 2025).
These expectations show why a global FSP partnership cannot operate as a series of isolated placements. The professionals may be located in different countries, but their work must connect through common governance, communication, documentation, performance management, and escalation processes.
The World Health Organization similarly describes strong clinical research as dependent on a broader ecosystem. Its guidance highlights sustainable infrastructure, workforce development, collaboration, coordinated regulatory and ethics systems, local engagement, and risk-proportionate oversight as important elements of effective clinical trials (World Health Organization, 2024).
This ecosystem perspective is especially relevant when sponsors enter emerging or less familiar markets. Local professionals may bring valuable country knowledge, but they still need access to the study’s global strategy, sponsor procedures, technology, training, and decision-making pathways. At the same time, the sponsor needs reliable mechanisms for understanding local developments.
A capable FSP provider helps create that connection. It supports onboarding, clarifies responsibilities, facilitates communication, monitors delivery, and helps ensure that regional issues reach the appropriate sponsor stakeholders. The provider should also maintain continuity when workloads change, professionals transition, or a study expands to additional countries.
Scalability must therefore be assessed operationally, not numerically. Adding ten professionals is not successful scaling if their roles are unclear, onboarding is delayed, or their work produces inconsistent outputs. Meaningful scaling occurs when additional capacity can be incorporated without weakening quality, communication, or sponsor visibility.
The ABRS model combines regional clinical research professionals with a structured operational framework. Professionals work according to sponsor and study requirements while receiving coordination and support designed to maintain alignment across functions and geographies.
This allows the sponsor to retain its standards and direction while using external expertise where and when it is needed. The result is a model that can respond to changing study demands without treating professionals as disconnected resources.
Conclusion:
Global clinical trials require global reach, but reach alone is not enough. Sponsors need partners that can convert geographic presence into dependable execution.
True global capability begins with regional knowledge. It requires an understanding of the regulatory, healthcare, cultural, and site-level conditions that shape study delivery in each market. It then depends on qualified professionals whose competence, experience, availability, and suitability have been evaluated against the actual assignment.
Finally, those professionals must be supported by a functioning delivery model. Clear responsibilities, efficient onboarding, common quality expectations, performance monitoring, communication pathways, escalation mechanisms, and continuity planning are what transform individual expertise into scalable operational capacity.
For sponsors, the key question should therefore not be simply, “Do you cover this country?” A more meaningful set of questions would be: Who can perform the work? How have they been evaluated? When can they begin? What structure will support them? How will we maintain visibility and consistency?
At ABRS, our Global FSP model is designed around these questions. We connect sponsors with experienced regional professionals while providing the operational alignment necessary to integrate those professionals into global clinical programs.
The strength of a global FSP provider should not be measured by the number of locations displayed on a map. It should be measured by how reliably the provider can mobilize the right expertise, in the right market, within a structure that protects quality, supports the sponsor, and delivers throughout the life of the study.
